首页 | 本学科首页   官方微博 | 高级检索  
     


Molecular modelling,synthesis and biological evaluation of peptide inhibitors as anti-angiogenic agent targeting neuropilin-1 for anticancer application
Authors:Ezatul E. Kamarulzaman  Amirah M. Gazzali  Muriel Barberi-Heyob  Cédric Boura  Céline Frochot
Affiliation:1. School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia;2. LCPM, UMR-CNRS 7375, Université de Lorraine, ENSIC, 1 Rue Grandville, F-54000 Nancy, France;3. LCPM, UMR-CNRS 7375, Université de Lorraine, ENSIC, 1 Rue Grandville, F-54000 Nancy, France;4. CRAN, UMR-CNRS 7039, Campus Science, BP 70239, F-54506 Vand?uvre-lès-Nancy, France;5. LRGP, UMR-CNRS 7274, Université de Lorraine, ENSIC, 1 Rue Grandville, F-54000 Nancy, France
Abstract:Vascular endothelial growth factor (VEGF) and its co-receptor neuropilin-1 (NRP-1) are important targets of many pro-angiogenic factors. In this study, nine peptides were synthesized and evaluated for their molecular interaction with NRP-1 and compared to our previous peptide ATWLPPR. Docking study showed that the investigated peptides shared the same binding region as shown by tuftsin known to bind selectively to NRP-1. Four pentapeptides (DKPPR, DKPRR, TKPPR and TKPRR) and a hexapeptide CDKPRR demonstrated good inhibitory activity against NRP-1. In contrast, peptides having arginine residue at sites other than the C-terminus exhibited low activity towards NRP-1 and this is confirmed by their inability to displace the VEGF165 binding to NRP-1. Docking study also revealed that replacement of carboxyl to amide group at the C-terminal arginine of the peptide did not affect significantly the binding interaction to NRP-1. However, the molecular affinity study showed that these peptides have marked reduction in the activity against NRP-1. Pentapeptides having C-terminal arginine showed strong interaction and good inhibitory activity with NRP thus may be a good template for anti-angiogenic targeting agent.
Keywords:neuropilin-1  VEGFR  angiogenesis  synthetic peptides  docking study  molecular modelling  ELISA  in vitro binding
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号